ColdZyme® reduces viral load and upper respiratory tract infection duration and protects airway epithelia from infection with human rhinoviruses

Documenti analoghi

• Symptom‐modifying strategy to treat upper respiratory tract infections: a clinical and mechanistic evidence of ColdZyme
  di: Maulana A. Empitu, et al.
  Pubblicazione: (2025)
• Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
  di: Posch, Wilfried
  Pubblicazione: (2022)
• Epigenetic training of human bronchial epithelium cells by repeated rhinovirus infections
  di: Marua Abu Risha, et al.
  Pubblicazione: (2024)
• Diffuse alveolar hemorrhage syndrome secondary to bocavirus and rhinovirus infection in a pediatric patient
  di: Carlos Eduardo Reina
  Pubblicazione: (2018)
• In Pursuit of New Paradigms: TASI 2024
  di: McCullough, Matthew
  Pubblicazione: (2024)